European Commission approves pharma trio’s Ranivisio
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union
Read More
Tag: retinal
NICE nod for Novartis’ Luxturna
The treatment has been approved for RPE65-mediated inherited retinal dystrophies.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
